For people with rare diseases, an accurate diagnosis is often the critical first step towards targeted treatment. Yet so-called orphan diagnostics are coming under pressure and may increasingly disappear from the market – with serious consequences for patient care. The current IVDR reform offers a real opportunity to change that. Read on to find out what this means for IVD manufacturers.